Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comprehensive Review on Various Aspects of Sars-Cov-2 (Covid-19) Vaccines Publisher



Pordanjani SR1, 2 ; Pordanjani AR3 ; Askarpour H4 ; Arjmand M4 ; Babakhanian M5 ; Amiri M6 ; Mazaheri E7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Social Determinants of Health Research Center, Semnan, Iran
  2. 2. Department of Epidemiology and Biostatistics, School of Medicine, Semnan, Iran
  3. 3. Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran
  4. 4. Department of Disease Management, Deputy of Health, Yasuj University of Medical Sciences, Shahrekord, Iran
  5. 5. Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
  6. 6. Department of Disease Management, Deputy of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
  7. 7. Health Information Technology Research Center, Students Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Source: International Journal of Preventive Medicine Published:2022


Abstract

This is a comprehensive review based on the published papers in the field of COVID-19 vaccines and vaccination. Many efforts have been made to develop vaccines to combat this pandemic. Since December 2020, more than 200 vaccines have been tested in various research stages and in clinical trials on humans, of which eight vaccines reached phase four clinical trials in humans and approved by FDA and EUA. After the Pfizer-BioNTech vaccine that had the highest efficacy (95%), the efficacy of the other vaccines are as follows: Moderna 94.5%, Sputnik V 91%, Novavax 89.7%, Sinopharm 79.3%, Oxford/AstraZenaca 70.4%, Johnson and Johnson 66.9%, and Sinovac 50.7%. At present, protein-based vaccines, with 35% of all available COVID-19 vaccines, are the most common technique in the vaccine production, and then there are vaccines of non-replicating viral vector (13.3%), mRNA1 (12.1%), DNA (10.2%), replicating viral vector (9.8%), and inactivated vaccines (8.2%). The most frequently recognized adverse effects within 7 days of each vaccine dose involved fever, fatigue, headache, chill, and myalgia. The mRNA-based vaccines were associated with a higher occurrence of local side effects (78.3 vs. 70.4%; Sig. = 0.064), whereas the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (87.2 vs. 61%; Sig. < 0.001). Based on the evidence and articles in the field of vaccination, AstraZeneca-Oxford and Sinopharm vaccines reported the highest and lowest side effects, respectively. Because of being emerging, pathogenicity, and high infectivity of COVID-19, vaccination against the disease to prevent its incident rate and decrease the prevalence rate is recommended immediately. Being informed of various aspects of the existing vaccines such as efficacy, effectiveness, safety, etc.can accelerate to make effective and useful choices and consequently have a vaccinated community against the epidemic. © 2022 International Journal of Preventive Medicine.
Related Docs
View other Related Docs
1. Safety, Acceptance, and Hesitancy of Covid-19 Vaccines Among High-Risk Sub-Populations: A Narrative Review, Journal of Pediatrics Review (2023)
2. Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of Covid.19 Pandemic: A Narrative Review, International Journal of Preventive Medicine (2021)
3. Vaccine Design and Delivery Approaches for Covid-19, International Immunopharmacology (2021)
4. Efficacy and Side Effects of Sputnik V, Sinopharm and Astrazeneca Vaccines to Stop Covid-19; a Review and Discussion, Immunopathologia Persa (2021)
5. Covid-19 Vaccines: Current and Future Challenges, Frontiers in Pharmacology (2024)
6. Association of Prior Covid‑19 Infection With Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran, International Journal of Preventive Medicine (2024)
7. Comparative Study of the Level of Neutralizing Antibodies in People Injecting 4 Types of Covid-19 Vaccine; [بررسیمقایسهایسطح آنتیبادیخنثیکنندهدر افراد تزریقکنندهی4نوع واکسن کووید-], Journal of Isfahan Medical School (2024)
8. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
Experts (# of related papers)
View all Related Experts
Hossein Khanahmad (5)
Shaghayegh Haghjooy Javanmard (4)
Other Related Docs
9. The Mrna Vaccines and Their Application to Combat Infectious Diseases and Cancers: A Review Article, Journal of Isfahan Medical School (2023)
10. Cardiovascular Complications of Sars-Cov-2 Vaccines: An Overview, Cardiology and Therapy (2022)
11. Convalescent Plasma Therapy for Covid-19: Lessons From Sars-Cov, Mers-Cov, and H1n1 Infection, Acta Medica Indonesiana (2021)
12. Drug Repositioning Approach to Target Viral and Host Cells in Terms of Covid-19 Treatment: A Review of in Vivo Experiments and Clinical Studies, Journal of Experimental and Clinical Medicine (Turkey) (2022)
13. Comparative Analysis and Identification of Spike Mutations in Iranian Covid-19 Samples From the First Three Waves of Disease, Advanced Biomedical Research (2023)
14. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
15. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran, Vaccines (2022)
16. Vaccine-Associated Complications: A Comparative Multicenter Evaluation Among Dental Practitioners and Dental Students—Which Candidate Vaccine Is More Safe in Sars Cov Ii, Gam-Covid-Vac (Sputnik V), Chadox1 Ncov-19 (Astrazeneca), Bbv152 (Covaxin), or Bbibp-Corv(Sinopharm)?, Maxillofacial Plastic and Reconstructive Surgery (2022)
17. Covid-19 Breakthrough Infections Among Patients With Cancer Receiving Sinopharm Bibp Vaccine, International Journal of Cancer Management (2022)
18. Novel Sars-Cov2 Poly Epitope Phage-Based Candidate Vaccine and Its Immunogenicity, Research in Pharmaceutical Sciences (2024)
19. Evaluation of Humoral and Cellular Immune Responses Against Vibrio Cholerae Using Oral Immunization by Multi-Epitope-Phage-Based Vaccine, International Immunopharmacology (2024)
20. Importance of the Covid-19 Vaccine Booster Dose in Protection and Immunity, Vaccines (2022)
21. Epidemiological Study of Covid-19 in Iran and the World: A Review Study, Infectious Disorders - Drug Targets (2022)
22. Immunoprotective Effect of an in Silico Designed Multiepitope Cancer Vaccine With Boris Cancer-Testis Antigen Target in a Murine Mammary Carcinoma Model, Scientific Reports (2021)
23. Evaluation of Anti-Sars-Cov-2 Rbd Antibody Response After Booster Dose of Spikogen® in Individuals With Two Previous Doses of Sinopharm and Its Association With Hla-Dr and -Dq Alleles, Human Immunology (2025)
24. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
25. Exploring the Out of Sight Antigens of Sars-Cov-2 to Design a Candidate Multi-Epitope Vaccine by Utilizing Immunoinformatics Approaches, Vaccine (2020)
26. Cardiovascular Complications of Covid-19 Vaccines: A Review of Case-Report and Case-Series Studies, Heart and Lung (2023)
27. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)
28. Monitoring and Active Surveillance of Adverse Events Following the Booster Dose of Azd1222 Vaccine in People Vaccinated With Sinopharm Bbibp-Corv: A Cohort Study, BMC Public Health (2025)
29. The Effect of Covid-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran, Iranian Journal of Public Health (2022)
30. Novel Drug and Vaccine Delivery Systems, Journal of Isfahan Medical School (2012)
31. In-Silico Design of a New Multi-Epitope Vaccine Candidate Against Sars-Cov-2, Acta Virologica (2023)
32. Sars-Cov-2 Serology Among People With Multiple Sclerosis on Disease-Modifying Therapies After Bbibp-Corv (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine, Multiple Sclerosis and Related Disorders (2022)
33. Covid-19 Management in the Emergency Ward, Journal of Research in Medical Sciences (2021)
34. Genetics and Genomics of Sars-Cov-2: A Review of the Literature With the Special Focus on Genetic Diversity and Sars-Cov-2 Genome Detection, Genomics (2021)
35. A Comprehensive Review of Therapeutic Options for Covid-19, Ethiopian Journal of Health Development (2022)
36. Subcutaneous Administration of a Fusion Protein Composed of Pertussis Toxin and Filamentous Hemagglutinin From Bordetella Pertussis Induces Mucosal and Systemic Immune Responses, Iranian Journal of Basic Medical Sciences (2018)
37. Chitin and Chitosan As Tools to Combat Covid-19: A Triple Approach, International Journal of Biological Macromolecules (2021)
38. Outlook of Therapeutic and Diagnostic Competency of Nanobodies Against Sars-Cov-2: A Systematic Review, Analytical Biochemistry (2022)
39. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
40. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy, Frontiers in Immunology (2022)
41. Phage Based Vaccine: A Novel Strategy in Prevention and Treatment, Heliyon (2023)
42. Immunogenicity of Covid-19 Vaccines in Patients With Diabetes Mellitus: A Systematic Review, Frontiers in Immunology (2022)
43. Potential Inhibitors of Sars-Cov-2: Recent Advances, Journal of Drug Targeting (2021)
44. Third Covid-19 Vaccine Dose for People With Multiple Sclerosis Who Did Not Seroconvert Following Two Doses of Bbibp-Corv (Sinopharm) Inactivated Vaccine: A Pilot Study on Safety and Immunogenicity, Frontiers in Immunology (2023)
45. Unraveling the Mystery of Covid-19 Postvaccination Myocarditis: A Systematic Review of Current Cases, International journal of clinical practice (2022)
46. Construction and Evaluation of Dna Vaccine Encoding Fusion Protein of Hepatitis C Virus Core Protein and Hepatitis B Surface Antigen As a Vaccine Candidate, Journal of Isfahan Medical School (2013)
47. Sars-Cov-2 Vaccines: A Double-Edged Sword Throughout Rapid Evolution of Covid-19, Cell Biology International (2022)
48. Effectiveness of Bbibp-Corv Vaccine in Preventing Sars-Cov2 Infection and Severe Outcomes in People Living With Multiple Sclerosis: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
49. Leishmania Vaccines Entered in Clinical Trials: A Review of Literature, International Journal of Preventive Medicine (2019)
50. Incidence of Bell's Palsy After Coronavirus Disease (Covid-19) Vaccination: A Systematic Review and Meta-Analysis; [Incidencia De La Paralisis De Bell Despues De La Vacunacion Contra La Covid-19: Una Revision Sistematica Y Un Metanalisis], Neurologia (2024)